SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The Fund disclosed its NAV per Class I share of $25.87 as of April 30, 2026, aggregate NAV of $1,039.0 million, portfolio composition of 171 companies with $2,076.9 million fair value, and leverage metrics of 1.20x debt-to-equity, providing investors with material information on the Fund's financial condition and risk profile.
View raw filing on EDGAR →The filing discloses a monthly distribution declaration for a real estate investment trust (REIT), specifying gross and net per-share amounts ($0.1927 gross, varying net by share class) payable on June 18, 2026. While distribution announcements are routine for REITs, this disclosure under Item 7.01 (Regulation FD) rather than a dedicated Item suggests it may carry material significance to investors assessing the REIT's cash generation and dividend sustainability. However, the taxonomy lacks a specific "dividend_distribution" category, and the event does not fit cleanly into earnings_release (no financial results) or other defined types.
View raw filing on EDGAR →Antares Private Credit Fund declared a regular distribution of $0.1887 per share, payable June 29, 2026, affecting shareholder cash flow expectations.
View raw filing on EDGAR →The fund disclosed key performance metrics including NAV per share of $24.69 as of April 30, 2026, aggregate NAV of $802.8 million, a debt-to-equity ratio of 1.18x, and ongoing offering progress of $817 million raised through May 1, 2026.
View raw filing on EDGAR →The filing discloses a spin-off and separation of First Tracks Biotherapeutics, Inc. from AnaptysBio, with distribution of First Tracks common stock to stockholders. While the Item 7.01 disclosure itself is limited to tax guidance (Form 8937), the underlying transaction—a material corporate separation and dividend distribution—is a significant capital structure event that would materially affect investor assessment. This does not fit neatly into ma_activity (which typically covers acquisitions/mergers rather than spin-offs), so other_material is most appropriate.
View raw filing on EDGAR →The filing discloses a draw of $1.7 million under a $50 million revolving credit facility established on April 21, 2026 with Parkview Holdings One LLC. While Item 2.03 is the appropriate disclosure vehicle for creation of direct financial obligations, this particular event—the first draw under a previously disclosed credit facility—is a routine drawdown rather than a material new obligation event. The material event (the Loan Agreement itself) was disclosed on April 22, 2026; this May 26 draw is administrative follow-through. However, marked material=true because the $50 million facility and its use for general corporate purposes could be significant to investor assessment of the company's liquidity and capital structure.
View raw filing on EDGAR →American Airlines entered into a Twelfth Amendment to its credit agreement on May 29, 2026, refinancing $1,146.8 million in existing term loans and incurring an additional $703.2 million in incremental term loans, totaling $1,850 million in new debt maturing in 2033. This material debt refinancing and incremental borrowing transaction affects the company's capital structure and liquidity.
View raw filing on EDGAR →The disclosure announces a board decision to consider resumption of quarterly dividends and schedule a special meeting for July 29, 2026. While filed under Item 2.02 (Results of Operations and Financial Condition), the substance is a corporate governance/capital allocation announcement rather than a financial results disclosure. Dividend resumption is material to shareholders but does not fit cleanly into earnings_release, exec_compensation, or shareholder_vote_results categories, warranting classification as other_material.
View raw filing on EDGAR →Stockholders approved an amendment to the Company's Certificate of Incorporation at the May 22, 2026 Annual Meeting increasing authorized shares of common stock from 312.3 million to 452.8 million shares and preferred stock from 24.1 million to 34.9 million shares, materially expanding the Company's capacity to issue equity.
View raw filing on EDGAR →The disclosure describes the consummation of Aperture AC's IPO on May 22, 2026, raising $102 million in gross proceeds from the sale of 10.2 million units at $10.00 per unit, plus a concurrent private placement of 311,000 units for $3.11 million. While this is a material capital-raising event affecting the registrant's financial position, it does not fit cleanly into the earnings_release, ma_activity, or dilutive_issuance categories—it is a SPAC IPO with trust account mechanics rather than a traditional equity offering or M&A transaction. Classified as other_material given its significance to a reasonable investor but lack of precise categorical fit.
View raw filing on EDGAR →The Company drew $5,000 thousand under an unsecured promissory note from its sponsor to extend its business combination deadline from May 29, 2026 to June 29, 2026. While this creates a direct financial obligation (Item 2.03), it is a routine extension mechanism for a SPAC that does not fit neatly into the more specific event categories. The disclosure is material because it signals continued inability to close a business combination and reliance on sponsor funding, which affects investor assessment of the Company's prospects.
View raw filing on EDGAR →The 8-K discloses two press releases announcing "business developments" on May 20 and May 27, 2026, along with a "Pre-Paid Purchase" agreement with Streeterville Capital dated May 22, 2026. Without access to the actual press release content, the specific nature of these developments cannot be determined from the Item 8.01 disclosure alone. The reference to a pre-paid purchase agreement suggests potential financing or capital activity, but the exact materiality and event classification depend on the substance of the announcements, which are incorporated by reference but not detailed in the filing excerpt provided.
View raw filing on EDGAR →The company provided a material update on the development program for ATNM-400, a product candidate, disclosed via press release in connection with receipt of a Notice.
View raw filing on EDGAR →Matternet entered into a material definitive agreement, as disclosed under Item 1.01. Without substantive details on the agreement's parties, terms, or business purpose, the specific event classification cannot be determined with confidence.
View raw filing on EDGAR →Matternet made a material modification to the rights of security holders, as disclosed under Item 3.03. The specific nature of the modification (e.g., charter amendment, voting rights change) cannot be determined from the item heading alone.
View raw filing on EDGAR →Matternet experienced a change in shell company status, as disclosed under Item 5.06. This change materially affects the registrant's regulatory classification and investor protections.
View raw filing on EDGAR →WisdomTree disclosed entry into privately negotiated repurchase agreements to buy back approximately $51.9 million in principal amount of its 3.25% Convertible Senior Notes due 2029 for $87.3 million in cash. This is a material capital allocation and debt reduction event that would affect investor assessment of the company's financial position and leverage, but it does not fit cleanly into the more specific event categories (not M&A, not a covenant breach, not a dilutive issuance). The transaction is material and disclosed under Item 8.01 as an "Other Event."
View raw filing on EDGAR →This Item 2.03 disclosure describes the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines, which are joint and several obligations of all eleven Federal Home Loan Banks. While the filing creates direct financial obligations through debt issuance, the prose emphasizes that the Bank has "not made a judgment as to the materiality of any particular consolidated obligation or obligations" and focuses on regulatory framework and reporting methodology rather than a specific material debt event. The disclosure is material to the Bank's operations but does not fit cleanly into the covenant_breach or other specific debt-related categories, as it describes routine consolidated obligation issuance mechanics rather than a triggering financial event.
View raw filing on EDGAR →The disclosure announces new clinical data for Moleculin's lead drug candidate Annamycin presented at ASCO, highlighting a "differentiated cardiac safety profile." This is material clinical trial progress for a biotech company with a lead candidate in development, as it addresses a critical safety concern that could influence investor assessment of the drug's commercial viability and regulatory pathway. However, it does not fit neatly into earnings_release (no financial results), material_litigation, or other more specific categories, making other_material the most appropriate classification.
View raw filing on EDGAR →Monopar disclosed Phase 2 clinical trial results for ALXN1840 (tiomolibdate choline) in Wilson disease patients presented at a major medical conference (EASL 2026). While this represents material clinical progress for a therapeutic candidate, it does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, executive change, or financial restatement). Clinical trial results presented at conferences are typically material to investors assessing pipeline value and development progress, warranting classification as other_material.
View raw filing on EDGAR →Classover Holdings, Inc. amended its certificate of incorporation to change its legal name to 'KIDZ AI Inc.' effective May 26, 2026. The corporate name change is a material event affecting investor identification and security trading.
View raw filing on EDGAR →LyondellBasell entered into an Eighth Amendment to its structured accounts receivable facility, extending the term to June 2027 and reducing the maximum available amount from $900 million to $700 million. This amendment materially affects the Company's liquidity and financing structure.
View raw filing on EDGAR →The filing discloses a press release announcing the launch of a 50+ physical qubit neutral-atom quantum computer with targets for thousands of qubits by end of H1 2027. This represents a significant product milestone and technological achievement for a quantum computing company, but does not fit neatly into standard 8-K event categories (not earnings, M&A, executive changes, impairment, litigation, or cybersecurity). The announcement is material to investors assessing the company's progress and competitive position in quantum computing, warranting disclosure under Item 8.01 (Other Events).
View raw filing on EDGAR →The Company disclosed an inadvertent error in its Definitive Proxy Statement filed May 12, 2026, where the record date for the annual meeting was incorrectly stated as May 12, 2026 when the correct date is May 14, 2026. This error affects stockholder voting eligibility and requires filing a revised proxy statement. While not fitting the specific "restatement" category (which applies to financial statements), this is a material disclosure correction that would affect a reasonable investor's ability to participate in the annual meeting vote.
View raw filing on EDGAR →BD discloses resumption of ChloraPrep™ and PurPrep™ shipments after a voluntary hold in response to an FDA Warning Letter for the El Paso manufacturing facility. While the disclosure emphasizes acceptable testing results and no patient safety signals, the underlying regulatory action (FDA Warning Letter) and product shipment disruption are material to investors assessing operational and regulatory risk, even though the immediate disclosure is framed positively.
View raw filing on EDGAR →The filing discloses a Board declaration of a $0.01 per common share distribution with a 1.7% annualized yield, filed under Item 2.02 (Results of Operations and Financial Condition). While distribution declarations are material to shareholders, this does not fit cleanly into earnings_release (no financial results disclosed), exec_compensation (not executive-focused), or other specific event types. The disclosure is material to investors assessing income and capital allocation, but the Item 2.02 placement and lack of detailed financial results create ambiguity about whether this is a routine distribution announcement or a material financial event warranting 8-K disclosure.
View raw filing on EDGAR →Carter Bankshares disclosed a strategic portfolio repositioning involving the sale of $139.4 million in securities at a pre-tax loss of approximately $12.5 million, with reinvestment of $88.5 million in higher-yielding securities. While this is a material financial event affecting Q2 2026 results and expected to improve annual interest income by $4.2 million, it does not fit cleanly into the specific event categories (not an impairment charge, not M&A, not an earnings release). The disclosure is material to investors as it affects reported earnings and future net interest income, but the event is best classified as a material portfolio management action outside the standard taxonomy.
View raw filing on EDGAR →This Item 8.01 disclosure reports the Company's NAV per share as of April 30, 2026 ($20.12–$20.16 across share classes), aggregate NAV of $744 million, and the status of an ongoing public offering of up to $2.0 billion in shares. While NAV reporting is routine for closed-end funds and BDCs, the disclosure of offering progress (32.9 million shares issued for $664 million in total consideration) and the Company's intention to continue monthly share sales is material to investors assessing the Company's capital-raising trajectory and share dilution. The event does not fit neatly into more specific categories (not earnings, M&A, impairment, or dilutive issuance in the traditional sense), making `other_material` the most appropriate classification.
View raw filing on EDGAR →This disclosure announces a distribution declaration for multiple share classes of a REIT, specifying gross distributions, shareholder servicing fees, and net distributions payable on June 22, 2026. While distributions are routine for REITs and disclosed via Regulation FD, this does not fit cleanly into the standard taxonomy—it is neither an earnings release (no financial results), nor compensation, nor an executive event. The materiality is ambiguous: distributions are economically significant to shareholders but are expected recurring events for REITs. Classified as other_material given the disclosure's relevance to investor returns but lack of fit within more specific event categories.
View raw filing on EDGAR →The filing discloses a declared distribution to shareholders across multiple share classes with specific per-share amounts and payment dates. While distribution declarations are routine for REITs and closed-end funds, this disclosure under Item 7.01 (Regulation FD Disclosure) rather than a standard distribution announcement suggests the company chose to make this a material event filing. However, the event does not fit cleanly into the standard taxonomy categories—it is neither an earnings release (no financial results), nor compensation, nor any other defined event type. The materiality to investors is moderate: distributions affect shareholder returns but are typically expected and recurring for this asset class.
View raw filing on EDGAR →IBM disclosed a $10B strategic investment plan over 5 years to advance quantum computing leadership, including R&D, capex, ecosystem partnerships, manufacturing, and M&A, with a target to deliver the first large-scale fault-tolerant quantum computer by 2029. This announcement also references a Letter of Intent with the Department of Commerce for a quantum chip foundry. While this involves forward-looking strategic commitments and potential M&A activity, the disclosure is primarily a strategic business initiative and capital allocation announcement rather than a completed M&A transaction, earnings release, or other specifically-defined event type. The material nature and investor significance warrant classification as a material event outside the more specific taxonomy categories.
View raw filing on EDGAR →The disclosure announces completion of the 2026-2027 reinsurance program for UPCIC and APPCIC, effective June 1, 2026, with detailed specifications of retention levels, coverage towers, and reinstatement provisions. For an insurance company, reinsurance program placement is material to investors as it directly affects the company's ability to manage catastrophic loss exposure and financial stability. However, this is a routine operational disclosure rather than a triggering event (like a covenant breach, impairment, or going-concern issue), so it does not fit the more specific event categories and is best classified as other_material.
View raw filing on EDGAR →HIS Kingdom Holdings LLC (managed by Board member Timothy Newell) is purchasing 11,905 Class A Common Units and 11,905 Series A Preferred Units from Navy Federal Credit Union, with Board consent granted on May 14, 2026 and anticipated closing by June 30, 2026. This material change in unit ownership structure involves a related-party transaction.
View raw filing on EDGAR →The filing discloses a press release announcing "RAD Construction Momentum Continues with Additional RIO and ROSA Orders," indicating new customer orders for the company's robotics products. While the specific financial impact is not quantified in the Item 8.01 disclosure itself, the announcement of material orders for the company's core products (RIO and ROSA robots) would reasonably affect an investor's assessment of business momentum and revenue prospects. This does not fit neatly into earnings_release (no financial results disclosed) but represents a material business development that warrants disclosure under Item 8.01.
View raw filing on EDGAR →The Board of Directors authorized a $1.0 billion share repurchase program, representing a material capital allocation decision that affects shareholder value and the company's financial flexibility.
View raw filing on EDGAR →The Company announced formal certification by NOAA of its USA B exploration license application under the Deep Seabed Hard Mineral Resources Act. This represents a significant regulatory milestone for the Company's deep-sea mining operations and would materially affect investor assessment of the registrant's ability to pursue its core business strategy. While not fitting neatly into standard M&A or operational categories, the certification of an exploration license is a material event that a reasonable investor would consider important to the registrant's prospects.
View raw filing on EDGAR →PENN Entertainment amended its $962.5 million Term Loan B facility on May 28, 2026, repricing the interest rate margins downward (from 2.50% to 2.00% for SOFR loans) and extending the maturity to May 2033. This debt refinancing materially affects the company's debt structure and cost of capital.
View raw filing on EDGAR →Medalist's subsidiary OWN has entered into a $15.8 million Pledged Asset Line (PAL) Agreement with Charles Schwab, a material financing arrangement secured by a brokerage account. While this is a credit facility disclosure rather than a covenant breach or going-concern issue, the establishment of a significant margin credit facility with customary default triggers (including bankruptcy initiation and collateral insufficiency) is material to investors assessing the company's liquidity and financial obligations, but does not fit neatly into the more specific event categories.
View raw filing on EDGAR →The filing discloses two distinct events: (1) a segment reorganization moving a titanium alloy location from Engine Products to Engineered Structures, which the company explicitly states had "no impact on the Company's consolidated results, financial position or cash flows" and is not a restatement; and (2) a material debt refinancing transaction on May 22, 2026, involving early prepayment of ¥29,702 million in JPY Term Loan debt and entry into a cross-currency swap on $300 million of 6.750% Notes due 2028, expected to reduce annual interest expense by approximately $12 million. The segment reorganization is administrative and immaterial, but the debt refinancing is a material financial transaction affecting the company's capital structure and interest expense. This combination does not fit cleanly into a single taxonomy category (not a restatement, not a covenant breach, not M&A), making "other_material" the most appropriate classification.
View raw filing on EDGAR →The Board approved a $40 million share repurchase program on May 28, 2026, which is a material capital allocation decision that would affect investor assessment of the company's financial strategy and use of cash. While share repurchases are common corporate actions, a $40 million authorization represents a significant commitment of capital and signals management's confidence in valuation. This does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, or financial restatement), making "other_material" the most appropriate classification.
View raw filing on EDGAR →Hudson Technologies received a bridge modification from the Defense Logistics Agency extending an existing contract expiration from July 29, 2026 to November 29, 2026, with two additional three-month renewal options. While this is a material contract extension for a significant government customer (DLA), it does not fit neatly into the more specific event categories (not M&A, not an impairment, not a covenant breach). The extension of a major defense contract is material to investor assessment of the company's revenue continuity and operational stability, warranting disclosure as an other_material event.
View raw filing on EDGAR →ClearSign suspended and terminated its ATM (At The Market) prospectus supplement on May 26, 2026, halting the ability to sell up to $10.39 million in common stock under the ATM Agreement. While this is a material event affecting the company's capital-raising capacity, it does not fit cleanly into the dilutive_issuance category (which applies to actual unregistered sales) nor any other specific taxonomy event. The suspension of an active equity offering program is material to investors assessing the company's liquidity and financing flexibility, warranting disclosure as other_material.
View raw filing on EDGAR →Aflac issued approximately ¥65.9 billion in registered senior notes across four tranches (2029, 2031, 2033, and 2036) on May 28, 2026, pursuant to a public offering under Form S-3ASR. While this is a material debt issuance that would affect a reasonable investor's assessment of the company's capital structure and financial position, it does not fit cleanly into the more specific event categories. This is a registered debt offering (not an unregistered equity issuance triggering dilutive_issuance), not a covenant breach, and not an M&A activity. The disclosure is material but best classified as other_material given the taxonomy's focus on equity issuances and specific debt-related events like covenant breaches.
View raw filing on EDGAR →Ionis disclosed positive Phase 3 pivotal trial results for bepirovirsen, a partnered investigational drug for chronic hepatitis B licensed to GSK, demonstrating a 19% functional cure rate and meeting primary endpoints with clinical efficacy superior to standard of care. This material clinical milestone affects investor assessment of the company's pipeline prospects and partnership value.
View raw filing on EDGAR →The filing discloses termination of the 2027 Notes ($400 million principal) through redemption using proceeds from a new $400 million 2031 Notes issuance. While this involves debt refinancing, it does not fit cleanly into the standard taxonomy: it is neither a covenant breach (no default triggered), nor a material impairment, nor a dilutive equity issuance. The event is material to investors as it affects the company's capital structure and debt maturity profile, but the specific mechanics—a routine debt refinancing—lack the acute financial distress signals of other categories.
View raw filing on EDGAR →The Fund reported its NAV per share of $26.10 as of April 30, 2026, aggregate NAV of $1,625.2 million, and key leverage metrics including a debt-to-equity ratio of 0.91x, along with progress on its continuous $2.5 billion public offering. This disclosure is material to investors assessing the fund's capital structure and growth trajectory.
View raw filing on EDGAR →Aveanna Healthcare entered into the thirteenth amendment to its First Lien Credit Agreement on May 26, 2026, resulting in a repricing of facilities with a 0.50% reduction to applicable interest rate margins and refinancing of $1.318 billion in term loans and a $250 million revolving credit facility. While this is a material debt refinancing that affects the company's capital structure and cost of borrowing, it does not fit neatly into the more specific event categories (not a covenant breach, not a going-concern disclosure, not a material impairment). The repricing and refinancing would be material to investors assessing the company's financial obligations and leverage position.
View raw filing on EDGAR →The filing discloses a material regulatory milestone: on May 27, 2026, the FDA released MannKind from a five-year postmarketing requirement to conduct a large randomized controlled trial (8,000-10,000 patients) assessing pulmonary malignancy risk with Afrezza. This removal of a significant regulatory burden is favorable to the company and would affect a reasonable investor's assessment of Afrezza's regulatory pathway and commercial prospects. The disclosure also updates clinical trial progress (INHALE-1st enrollment expansion) and a pending pediatric BLA with a May 29, 2026 PDUFA date. While this is primarily a positive regulatory/clinical update rather than a discrete event type (not a restatement, impairment, covenant breach, or other specific category), the material nature of the FDA's release from the postmarketing requirement warrants classification as a material event.
View raw filing on EDGAR →American Woodmark's Articles of Incorporation and Bylaws were amended and restated in connection with the merger closing, reflecting governance restructuring as part of the change of control transaction.
View raw filing on EDGAR →Material modifications to security holder rights were disclosed by reference to the Introductory Note and Item 3.01; the specific nature of the modifications cannot be determined from the Item 3.03 classification alone.
View raw filing on EDGAR →